Om

Oragenics Inc. is a clinical-stage biopharmaceutical company focused on intranasal drug delivery for neurological conditions and infectious diseases. The company’s current work centers on developing ONP-002, a lead neurosteroid candidate being studied for mild traumatic brain injury, including concussion. Oragenics uses proprietary nasal delivery technology designed to transport therapies directly to the brain, supporting targeted, non-invasive treatment approaches. Its platform also includes research in powdered drug formulations and other nasally delivered pharmaceutical products aimed at addressing unmet medical needs in neurology. Based in Florida, Oragenics positions itself within the biotechnology sector as a developer of specialized therapies for brain-related disorders and select infectious disease applications.

Analytikerskøn

Baseret på 1 analytiker

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I ORAGENICS MED ENDAVU: Køb Oragenics ($OGEN) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Oragenics, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.